Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy

Introduction. Although the role of TNF-α in tumor development is not fully understood, an increased risk of malignancy with TNF-α-inhibitors, such as infliximab, has been suggested. Case Presentation. We present a 54-year-old nonsmoking female sarcoidosis patient. After seven months of infliximab t...

Full description

Bibliographic Details
Main Authors:	Vorselaars, Adriane D. M., Sjögren, Elisabeth V., van Moorsel, Coline H. M., Grutters, Jan C.
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671292/

id	pubmed-3671292
recordtype	oai_dc
spelling	pubmed-36712922013-06-12 Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy Vorselaars, Adriane D. M. Sjögren, Elisabeth V. van Moorsel, Coline H. M. Grutters, Jan C. Case Report Introduction. Although the role of TNF-α in tumor development is not fully understood, an increased risk of malignancy with TNF-α-inhibitors, such as infliximab, has been suggested. Case Presentation. We present a 54-year-old nonsmoking female sarcoidosis patient. After seven months of infliximab therapy a T1aN0M0 larynx carcinoma of the right vocal cord was found and excised. Within a year, whilst still on treatment, a second larynx carcinoma of the opposite vocal cord appeared. Discussion. A bilateral vocal cord tumor is rare, especially in a never smoker. Evidence on the role of infliximab in carcinogenesis is inconclusive. To date, there are no follow-up studies evaluating malignancy risk of infliximab therapy in sarcoidosis patients. No studies in other diseases focus on laryngeal carcinomas during infliximab use. We argue that infliximab treatment might have attributed to the rapid progression of vocal cord carcinomas in this patient with an a priori low risk tumor profile. This case illustrates that caution remains warranted in patients with previous malignancies when considering initiation of TNF-α-inhibitors. Hindawi Publishing Corporation 2013 2013-05-15 /pmc/articles/PMC3671292/ /pubmed/23762724 http://dx.doi.org/10.1155/2013/308092 Text en Copyright © 2013 Adriane D. M. Vorselaars et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Vorselaars, Adriane D. M. Sjögren, Elisabeth V. van Moorsel, Coline H. M. Grutters, Jan C.
spellingShingle	Vorselaars, Adriane D. M. Sjögren, Elisabeth V. van Moorsel, Coline H. M. Grutters, Jan C. Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy
author_facet	Vorselaars, Adriane D. M. Sjögren, Elisabeth V. van Moorsel, Coline H. M. Grutters, Jan C.
author_sort	Vorselaars, Adriane D. M.
title	Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy
title_short	Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy
title_full	Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy
title_fullStr	Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy
title_full_unstemmed	Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy
title_sort	bilateral vocal cord carcinoma in a sarcoidosis patient during infliximab therapy
description	Introduction. Although the role of TNF-α in tumor development is not fully understood, an increased risk of malignancy with TNF-α-inhibitors, such as infliximab, has been suggested. Case Presentation. We present a 54-year-old nonsmoking female sarcoidosis patient. After seven months of infliximab therapy a T1aN0M0 larynx carcinoma of the right vocal cord was found and excised. Within a year, whilst still on treatment, a second larynx carcinoma of the opposite vocal cord appeared. Discussion. A bilateral vocal cord tumor is rare, especially in a never smoker. Evidence on the role of infliximab in carcinogenesis is inconclusive. To date, there are no follow-up studies evaluating malignancy risk of infliximab therapy in sarcoidosis patients. No studies in other diseases focus on laryngeal carcinomas during infliximab use. We argue that infliximab treatment might have attributed to the rapid progression of vocal cord carcinomas in this patient with an a priori low risk tumor profile. This case illustrates that caution remains warranted in patients with previous malignancies when considering initiation of TNF-α-inhibitors.
publisher	Hindawi Publishing Corporation
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671292/
_version_	1611983264936886272

Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy

Similar Items